Investment
Features
FeesSafety
Academy
More
Pluang+

Bank of America cuts Hims & Hers price target to $30 after mixed Q1 results and earnings miss.

Analyst Insights
13 May 2026
24/7 Wall Street
View Source
Bearish
pluang ai news

Bank of America lowered its price target for Hims & Hers Health to $30 from $32, maintaining a Neutral rating after the company's Q1 2026 results missed revenue and earnings expectations. The firm sees the need for a reset in market expectations due to challenges from transitioning U.S. weight loss treatments from compounded to branded GLP-1 drugs, which impacted revenue and led to restructuring charges. Despite the downgrade, other analysts remain divided, reflecting uncertainty about the company's valuation and strategic pivot. Investors are advised to be patient as the stock may need time to stabilize amid high valuation multiples and mixed growth signals.

More News (HIMS)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App